Biotech Family Offices Discuss Direct Investment at RESI Boston

24 Aug

By Lucy Parkinson, Director of Research, LSN

RESI Partnering is now open, providing attendees with the opportunity to book one on one meetings with investors.  If you log in to Partnering, you will see a wide variety of investors available to reach out to, including venture capital firms, big pharma, angels – and family offices.

RESI Boston’s Biotech Family Office sesssion features family office investors from around the world who are making direct investments into early stage drug development companies.  These firms have a variety of strategies, interests and motivations.  If you’d like to know how family office investors think about early stage drugs and what kind of technology catches their eye, this is the panel for you.

Moderated by Colin Widen (CEO, Boston Innovation Capital), the panelists are:

  • Christine Bunt (Venture Partner, 20/20 HealthCare Partners)
  • Pini Orbach (Head of Pharma, Arkin Bioventures)
  • Alex Pickett (Principal, Mediqventures)
  • Jayson Rieger (SVP of Business Development & Portfolio Management, PBM Capital)

We’ve extended the RESI discounted registration until Friday, so if you want to hear from these Biotech Family Offices now is the time to get registered.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: